Type IV Collagen in Human Colorectal Liver Metastases-Cellular Origin and a Circulating Biomarker.
CAF
COL IV
MMP
circulating biomarkers
colorectal cancer
fibroblasts
liver metastases
tumor stroma
type IV collagen
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
13 Jul 2022
13 Jul 2022
Historique:
received:
18
05
2022
revised:
30
06
2022
accepted:
11
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Circulating type IV collagen (cCOL IV) is a potential biomarker for patients with colorectal liver metastases (CLM) who present with elevated levels of COL IV in both CLM tissue and circulation. This study aimed to establish the cellular origin of elevated levels of COL IV and analyze circulating COL IV in CLM patients. The cellular source was established through in situ hybridization, immunohistochemical staining, and morphological evaluation. Cellular expression in vitro was assessed by immunofluorescence. Tissue expression of COL IV-degrading matrix metalloproteinases (MMPs)-2, -7, -9, and -13 was studied with immunohistochemical staining. Plasma levels of COL IV in CLM patients and healthy controls were analyzed with ELISA. This study shows that cancer-associated fibroblasts (CAFs) express COL IV in the stroma of CLM and that COL IV is expressed in vitro by fibroblasts but not by tumor cells. MMP-2, -7, -9, and -13 are expressed in CLM tissue, mainly by hepatocytes and immune cells, and circulating COL IV is significantly elevated in CLM patients compared with healthy controls. Our study shows that stromal cells, not tumor cells, produce COL IV in CLM, and that circulating COL IV is elevated in patients with CLM.
Identifiants
pubmed: 35884455
pii: cancers14143396
doi: 10.3390/cancers14143396
pmc: PMC9325127
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Cancer Res. 2016 May 15;22(10):2427-34
pubmed: 26673797
Surg Oncol. 2009 Mar;18(1):15-24
pubmed: 18619834
Front Cell Dev Biol. 2019 Apr 24;7:60
pubmed: 31106200
Eur J Surg Oncol. 2011 Jul;37(7):611-7
pubmed: 21620632
PLoS One. 2013 Aug 16;8(8):e70918
pubmed: 23976965
Ann Surg. 2006 Aug;244(2):254-9
pubmed: 16858188
Br J Cancer. 2008 Jul 8;99(1):68-71
pubmed: 18560403
N Engl J Med. 1978 Aug 31;299(9):448-51
pubmed: 683276
Matrix Biol. 2005 Oct;24(7):469-77
pubmed: 16139998
Br J Cancer. 2009 Jul 7;101(1):91-7
pubmed: 19491897
Breast Cancer Res Treat. 2009 Mar;114(1):47-62
pubmed: 18373191
Cancers (Basel). 2011 Apr 26;3(2):2160-8
pubmed: 24212801
Mol Cancer Res. 2006 May;4(5):293-302
pubmed: 16687484
Oncogene. 2011 Sep 1;30(35):3766-83
pubmed: 21478904
J Clin Oncol. 2006 Nov 20;24(33):5313-27
pubmed: 17060676
Dev Cell. 2019 May 6;49(3):332-346
pubmed: 31063753
JAMA. 1993 Aug 25;270(8):943-7
pubmed: 8141873
Oncotarget. 2016 Jun 14;7(24):36988-36999
pubmed: 27175590
Mol Cell Proteomics. 2012 Apr;11(4):M111.014647
pubmed: 22159717
Glob Health Action. 2010 Mar 22;3:
pubmed: 20339479
BMC Cancer. 2018 Jan 15;18(1):78
pubmed: 29334918
Enzyme Protein. 1996;49(1-3):20-37
pubmed: 8796995
Am J Physiol Gastrointest Liver Physiol. 2013 Mar 15;304(6):G605-14
pubmed: 23328207
J Biol Chem. 2019 Jan 4;294(1):281-289
pubmed: 30409905
Cancer Manag Res. 2020 Jun 22;12:4789-4797
pubmed: 32606968
Cancer Invest. 2005;23(4):338-51
pubmed: 16100946
Ann Surg. 1982 Aug;196(2):162-9
pubmed: 7046656
Oncol Rep. 2010 Nov;24(5):1241-7
pubmed: 20878116
Biomedicines. 2020 Aug 28;8(9):
pubmed: 32872372
Microsc Res Tech. 2008 May;71(5):357-70
pubmed: 18219669
World J Gastroenterol. 2012 May 7;18(17):2121-6
pubmed: 22563201
Mol Cancer Res. 2016 Mar;14(3):287-95
pubmed: 26631572
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncology. 2021;99(3):144-160
pubmed: 33027796
J Exp Clin Cancer Res. 2020 Aug 3;39(1):148
pubmed: 32746865
Clin Cancer Res. 2002 Jan;8(1):144-8
pubmed: 11801551
Br J Cancer. 2001 Jun 15;84(12):1664-70
pubmed: 11401321
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801
pubmed: 25415508
Blood. 1995 Feb 1;85(3):812-7
pubmed: 7833481
Oncologist. 2017 Sep;22(9):1067-1074
pubmed: 28550028
Anticancer Res. 2012 Dec;32(12):5183-91
pubmed: 23225415
BMC Cancer. 2013 Mar 26;13:154
pubmed: 23530721
J Cell Biol. 1982 Oct;95(1):340-4
pubmed: 6216257
J Surg Oncol. 1996 Aug;62(4):239-44
pubmed: 8691835
Pathol Int. 2002 Apr;52(4):255-64
pubmed: 12031080
Am J Gastroenterol. 1995 May;90(5):783-7
pubmed: 7733088
Dis Colon Rectum. 1994 Sep;37(9):875-81
pubmed: 8076486
Biochim Biophys Acta. 2015 May;1853(5):929-39
pubmed: 25686533
Clin Exp Metastasis. 2021 Apr;38(2):175-185
pubmed: 33655422
Ann Surg. 2008 Jan;247(1):125-35
pubmed: 18156932
Br J Surg. 2006 Apr;93(4):465-74
pubmed: 16523446
Int J Mol Sci. 2021 Aug 25;22(17):
pubmed: 34502094
J Clin Oncol. 2009 Aug 1;27(22):3677-83
pubmed: 19470929
J Med Syst. 1998 Apr;22(2):89-93
pubmed: 9571515
PLoS One. 2020 Jun 5;15(6):e0233687
pubmed: 32502149
FEBS J. 2011 Jan;278(1):16-27
pubmed: 21087457
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Sci Rep. 2016 Jul 28;6:30599
pubmed: 27465284
J Am Coll Surg. 2010 May;210(5):744-52, 752-5
pubmed: 20421043
J Biol Chem. 2019 May 24;294(21):8529-8542
pubmed: 30967475
Tumour Biol. 2015 Dec;36(12):9839-47
pubmed: 26162539
Scand J Surg. 2018 Dec;107(4):294-301
pubmed: 29692213
Am J Pathol. 2006 Mar;168(3):856-65
pubmed: 16507901
Clin Chem. 2001 Apr;47(4):624-30
pubmed: 11274010
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Exp Cell Res. 2016 May 15;344(1):53-66
pubmed: 27112989